An interventional study of Functional Snacks and Placebo Snacks in Perimenopause, Perimenopause-Related Depression and Mood, sponsored by King's College London. Recruiting at 1 site in United Kingdom. Open to female participants aged 40 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-05-20.
Sponsored by King's College London · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Depression by King's College London — 5 open to participants now, 8 under way, none of them phase 3. Depression · King's College London.
Among the 32 studies in Depression by King's College London, this one is the 22nd largest by planned enrollment of the 25 interventional ones that give a count, is the only one that started in 2026, is one of 22 with no phase, and was the 31st registered.
8,608 studies on the registry are indexed under Depression; 1,736 are open to participants now.
Browse Depression studies →5 of the 32 studies in Depression by King's College London are open now, in 1 country. Recruiting first, the newest first:
King's College London · Sites in United Kingdom
Ages 18+
King's College London · Sites in United Kingdom
Ages 18+
King's College London · Sites in United Kingdom
Ages 18+ · Women only
King's College London
Ages 18+
By country, each count listing its studies:
Of the 1,098 Depression studies recruiting now, 475 (43%) set no upper age limit and 522 (48%) stop at 75 or younger; 205 take children under 18; 315 take healthy volunteers.
This study: 40 Years to 55 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 2
First in 2003; this study’s year is marked. 1 started in 2026.
This study's planned enrollment of 20 is below the median of 81 across 7,089 interventional studies indexed under Depression.
Median enrollment 50 across the 25 interventional studies, 170 across the 7 observational. Of the 22 that completed or were terminated, 2 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
King's College London is the lead sponsor of 524 studies on the registry; 130 are open to participants now.
1 of the studies in Depression by King's College London that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07599930King's College LondonImpact of a Novel Functional Snack on Perimenopausal Symptoms and Well-being | 2026-12 |
Add it to your calendar (.ics) → With an account.
Among the 32 studies in Depression by King's College London, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a clinical trial aimed to investigate if a novel phytochemical and fibre-rich snack can improve perimenopausal symptoms and well-being in perimenopausal women aged 40-55 and not on hormone replacement therapy.
Hypothesis: The investigators hypothesise that the phytochemical and fibre-rich snack will improve perimenopausal symptoms via a gut microbiota mediated mechanism.
Main research questions:
Does eating the snack every day lower menopause symptoms such as hot flushes, night sweats, mood changes, and sleep problems? Does the snack improve mood, stress, anxiety, sleep, and overall quality of life? Does the snack improve the balance of bacteria in the gut, and could this be part of how it helps symptoms?
This double-blind, randomised, placebo-controlled crossover trial will assess the effects of daily consumption for 4 weeks of a novel phytochemical- and fibre-rich granola snack created by TulaCode on menopausal symptoms. The effects of the snack will be compared to a calorie-matched placebo snack: a commercially available oat bar low in fibre and polyphenols. The study will also examine the impact of the intervention snack on mood, stress, sleep quality, cognition, depression and anxiety. Participants will be randomly assigned to either the intervention or the placebo snack for 4 weeks followed by a 4-week washout period before crossing over to the alternate snack for another 4 week period. Snacks will be consumed twice daily, and participants will be instructed to maintain their usual diet and physical activity while avoiding additional probiotic, prebiotic, or polyphenol-rich supplements throughout the study.
Participants will attend 4 in-person study visits at King's College London. At baseline, after 4 weeks, after 8 weeks (washout period) and after 12 weeks. Each study visit will take approximately 1 hour. On the day before each study visit, participants will be asked to self-collect their saliva, 24-h urine and stool samples at home, as well as finish a set of online questionnaires, and be fasted for 12 hours prior to their study visit.
Self-collection procedure of participants at home one day before study visits:
Fill the below online questionnaires:
Weekly questionnaire, 4 questionnaires per visit:
Fill the below paper questionnaires:
On the morning of each study visit day, participants will bring their self-collected saliva, urine, and stool samples. Any Adverse events will be discussed and recorded. Any concomitant medication will be checked by the researchers that may impact on the eligibility criteria and the early completion of the study. Self-collected samples and completed online questionnaires will be checked. Blood pressure, heart rate and anthropometric measurements will be performed, waist-hip circumference will be measured, and fasting blood samples will be collected.
On Visit 1 (baseline), either intervention snack or a calorie-matched placebo snack will be provided to participants, with the amount should be enough for the 4-week study period. On Visit 3 (after 8 weeks), the crossover snacks will be provided to participants.
At the end of visit 1, 2 and 3, new self-collection kits and a link of online questionnaires will be distributed to participants to be used for next study visit.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Daily consumption of 2 pouches of function snacks (50 g per pouch, rich in phytochemicals and fibres) for 28 days, then crossing over to the placebo snacks
Dietary Supplement: Functional Snacks · Other: Placebo Snacks
Daily consumption of 2 pouches of placebo snacks (50 g per pouch, less in phytochemicals and fibres) for 28 days, then crossing over to the functional snacks
Dietary Supplement: Functional Snacks · Other: Placebo Snacks
A type of phytochemical and fibre rich snack that created and produced by TulaCode called Cinnamon Granola Bark (50 g per pouch). The snack contains the following ingredients: Amaranth, coconut flakes, chia seeds, pumpkin seeds, sunflower seeds, pecans, brazil nuts, almonds, dates, banana, cold pressed extra virgin olive oil, 100% cocoa mass, cocoa butter, chicory root fibre, cinnamon, cloves, nutmeg, ginger, ground vanilla pod, natural Bourbon vanilla flavouring, salt
A type of calorie-matched commercially available chocolate snack, Mini Cornflake Cluster Bites (50 g per pouch). The snack contains the following ingredients: Milk chocolate (60%) (sugar, cocoa butter, cocoa mass, skimmed milk powder, milk fat, lactose (milk), emulsifier (soya lecithin)), corn flakes (40%) (maize, sugar, salt, barley malt extract, dextrose, niacin, iron, vitamin B6, riboflavin, vitamin B1, folic acid, vitamin B12)
Changes in menopause rating scale (MRS) of perimenopausal women
To assess menopause-related symptoms of perimenopausal women, using the menopause rating scale (MRS). The scale consists in 11 items ranging from 0 (none) to 4 (very severe).
Time frame: Baseline & 4 weeks
Changes in subjective (perceived) stress level of perimenopausal women
The subjective stress level of perimenopausal women are assessed using the Perceived Stress Scale (PSS) questionnaire. The scale consists in 10 items rated on a 5-point Likert scale.
Time frame: Baseline & 4 weeks
Changes in affect in perimenopausal women
To assess the affect of perimenopausal women, using the Positive and Negative Affect Schedule (PANAS-SF) questionnaire, consisting of 20 items rated from 1 (very slightly or not at all) to 5 (extremely).
Time frame: Baseline & 4 weeks
Changes in female sex hormone levels of perimenopausal women
To assess the female sex hormone levels of perimenopausal women, measured several esterone levels in blood samples using the randox clinical biochemistry analyser.
Time frame: Baseline & 4 weeks
Changes in cognitive function of perimenopausal women
To assess cognitive function of perimenopausal womenm using Cognitive Failures questionnaire (CFQ). The questionnaire consists of 25 questions rated on a 5-point Likert scale from 0 ("Never") to 4 ("Very often").
Time frame: Baseline & 4 weeks
Changes in mental health and wellbeing metabolites level of perimenopausal women
To assess the metabolites related to mental health and wellbeing of perimenopausal women, measured a pack of metabolites/compounds including gut-brain axis metabolites, inflammatory markers, short-chain fatty acid, in plasma samples using Randox clinical biochemistry analyser and LC-MS.
Time frame: Baseline & 4 weeks
Habitual diet of perimenopausal women
Habitual diet is assessed via the food frequency questionnaire (FFQ), items ranging from "never" to "multiple times a day"-they consumed specific food and beverage items from a predefined list
Time frame: Baseline only
Gut microbiome of perimenopausal women
To investigate the role of the gut microbiome on the perimenopause symptoms. Gut microbiome diversity and composition will be analysed using 16s RNA sequencing technique as a pack.
Time frame: Baseline & 4 weeks
Changes in hormonal stress levels in perimenopausal women
Stress measured as the cortisol level changes in saliva samples by LC-MS, including the cortisol levels at 0 min, 15 min, 30 min and 60 min after wakening and 12 pm and 8 pm on the day.
Time frame: Baseline & 4 weeks
Changes in mood in perimenopausal women
To assess the overall changes in mood, using the Hospital Anxiety and Depression Scale (HADS), consist of 14 items rated on a 0-21 scale, with a higher score indicates a severe symptom.
Time frame: Baseline & 4 weeks
Changes in sleep quality in perimenopausal women
Sleep quality changes measured using Pittsburgh Sleep Quality Index (PSQI) questionnaire, consist of 19 items rated on a 0-3 scale with higher scores indicating poorer sleep quality.
Time frame: Weekly from baseline to 4 weeks
Changes in physical activity level in perimenopausal women
Changes in physical activity measured using the International Physical Activity questionnaire (IPAQ), producing a total activity score expressed in metabolic equivalent minutes per week (MET-min/week).
Time frame: Weekly from baseline to 4 weeks
Changes in quality of life in perimenopausal women
Changes in quality of life measured using the World Health Organisation Quality of Life Assessment Instrument (EF-WHOQOL-100), a 100 item questionnaire with responses rated on a 1-5 Likert scale
Time frame: Baseline & 4 weeks
Changes in gastrointestinal symptoms of perimenopausal women
Changes in the gastrointestinal function measured using Gastrointestinal Symptom Rating Scale (GSRS) questionnaire, consisting of 15 items rated from 1 (no discomfort) to 7 (very severe discomfort).
Time frame: Weekly from baseline to 4 weeks
Changes in weight of perimenopausal women
Weight will be measured in kilograms using a body composition analyser (Tanita BC-418 MA)
Time frame: Baseline & 4 weeks
Height of perimenopausal women
Height in centimeters will be measured using a stadiometer
Time frame: Baseline
Changes in BMI of perimenopausal women
Changes in BMI will be measured by weighing participants using the body composition analyser (Tanita BC-418 MA) and calculating BMI from participant height and weight
Time frame: Baseline & 4 weeks
Changes in hip-waist circumference of perimenopausal women
Hip and waist circumference will be measured in centimeters using a measuring tape
Time frame: Baseline & 4 weeks
Changes in blood pressure of perimenopausal women
Blood pressure will be measured using an electric sphygmomanometer blood pressure monitor in millimeters of mercury (mmHg).
Time frame: Baseline & 4 weeks
Heart rate of perimenopausal women
Heart rate will be measured in beats per minute using an electric sphygmomanometer blood pressure monitor
Time frame: Baseline & 4 weeks
Dietary polyphenol intake of perimenopausal women
Polyphenol intake measured via the Food-Frequency Questionnaire - Polyphenol. Food items are rated from "Never" to "More than 6 times per day".
Time frame: Baseline
Weekly diet of perimenopausal women
Weekly diet using Intake24, an online 24-hour dietary recall system that records all foods and drinks consumed during the previous day. It uses portion-size images and structured prompts to improve accuracy and reduce under-reporting.
Time frame: Weekly from baseline to week 4
Weekly diet of perimenopausal women
Weekly diet will be measured using OPIS, a mobile application using artificial intelligence to estimate the nutrients and components of meals. Participants take a picture of their meals for 24 hours in the application and AI breaks down the make-up of the food.
Time frame: Weekly from baseline to week 4
Plasma and Urinary metabolites of (poly)phenols of perimenopausal women
In total more than 160 phenolic compounds and phase 2 metabolites will be measured in plasma and urine samples by LC-MS.
Time frame: Baseline and 4 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2026 (actual). Primary completion is estimated for Dec 2026, 8 months after the start.
Of 3,486 non-industry interventional studies with no phase under Depression, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 8 months is below that.
Counting every sponsor, half of 3,584 studies reached it within 21 months; a quarter within 9 and three quarters within 41.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.